Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Osteogenesis Imperfecta: later-stage trial registry
3 of 14 indexed Osteogenesis Imperfecta trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 3 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Osteogenesis Imperfecta: 14 US clinical trials tracked, 3 recruiting.
Osteogenesis Imperfecta is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 5 of these trials.
Enrollment posture brief
Registry condition osteogenesis-imperfecta
OPEN 3 | RECR 21% | LATE 5 | EARLY 2 | RANK #1230 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)
Osteogenesis Imperfecta lists 3 open slots (21% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Osteogenesis Imperfecta on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Osteogenesis Imperfecta is recruiting below its size-band peers.
3 of 14 indexed trials (21.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Osteogenesis Imperfecta research.
Baylor College of Medicine accounts for 5 of 14 trials (35.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Osteogenesis Imperfecta enrolment sits around 88 participants.
Median target enrolment is 88 among the 14 trials that report a genuine target (sentinel values excluded). 8 of those (57.1%) plan for fewer than 100 participants.
-
Osteogenesis Imperfecta splits between interventional and observational designs.
8 interventional and 6 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
BBD Longitudinal Study of Osteogenesis Imperfecta
Baylor College of Medicine
NCT02432625
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Amgen
NCT05972551
Effects of Bisphosphonates on OI-Related Hearing Loss
Hospital for Special Surgery, New York
NCT04152551
Setrusumab vs Placebo for Osteogenesis Imperfecta
Ultragenyx Pharmaceutical
NCT05125809
Dental Malocclusion and Craniofacial Development in OI
Baylor College of Medicine
NCT02934451
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
Ultragenyx Pharmaceutical
NCT05768854
Clear Aligners for the Treatment of Dental Malocclusion in OI
Baylor College of Medicine
NCT04815564
Urinary Biomarkers of OI Pathobiology
Baylor College of Medicine
NCT02531087
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
Baylor College of Medicine
NCT05317637
Evaluation and Treatment of Patients With Connective Tissue Disease
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT00076830
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
Warner Chilcott
NCT00106028
Evaluation and Intervention for the Effects of Osteogenesis Imperfecta
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT00001594
Growth Hormone Therapy in Osteogenesis Imperfecta
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT00001305
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
Ultragenyx Pharmaceutical
NCT01417091
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Osteogenesis Imperfecta records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Osteogenesis Imperfecta trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Osteogenesis Imperfecta page
14 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Osteogenesis Imperfecta trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Osteogenesis Imperfecta trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Osteogenesis Imperfecta condition card totals 14 registered trials; most-linked intervention Setrusumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.